Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
SK Bioscience rolls out 1st batch of Novavax vaccine
2 million doses of Nuvaxovid expected to be rolled out by end of month
By Kan Hyeong-wooPublished : Feb. 9, 2022 - 15:55
SK Bioscience rolled out the first batch of Nuvaxovid, Novavax’s synthetic antigen-based COVID-19 vaccine, the company said Wednesday.
On top of the 840,000 doses that were rolled out on Wednesday, SK Bioscience said it plans to supply a total of 2 million doses by the end of this month. The shipment follows the Ministry of Food and Drug Safety’s approval of the vaccine last month.
In December, SK Bioscience signed a contract with the US bio firm to secure the manufacturing and supply rights in Korea, Thailand and Vietnam.
The local biopharmaceutical producer also had a deal with the government for the pre-purchase of 40 million doses of the vaccine. The vaccines will be distributed in steps under the Korea Disease Control and Prevention Agency’s plan, according to the company.
SK Bioscience said it expects Nuvaxovid to target a different market, as it is the country’s first synthetic antigen-based vaccine for the coronavirus. The company pointed out that synthetic antigen-based vaccines have proven their safety and efficacy, as they have been used for influenza and cervical cancer.
As Nuvaxovid can be stored at a temperature between 2 and 8 degrees Celsius, SK Bioscience said the latest vaccines can be delivered through the existing distribution network.
The mass-scale global clinical trials by Novavax showed a 90 percent prevention effect for Nuvaxovid against COVID-19, according to SK Bioscience. The company added that Nuvaxoid has shown immunity against the highly contagious omicron variant from Novavax’s recent studies.
On top of the 840,000 doses that were rolled out on Wednesday, SK Bioscience said it plans to supply a total of 2 million doses by the end of this month. The shipment follows the Ministry of Food and Drug Safety’s approval of the vaccine last month.
In December, SK Bioscience signed a contract with the US bio firm to secure the manufacturing and supply rights in Korea, Thailand and Vietnam.
The local biopharmaceutical producer also had a deal with the government for the pre-purchase of 40 million doses of the vaccine. The vaccines will be distributed in steps under the Korea Disease Control and Prevention Agency’s plan, according to the company.
SK Bioscience said it expects Nuvaxovid to target a different market, as it is the country’s first synthetic antigen-based vaccine for the coronavirus. The company pointed out that synthetic antigen-based vaccines have proven their safety and efficacy, as they have been used for influenza and cervical cancer.
As Nuvaxovid can be stored at a temperature between 2 and 8 degrees Celsius, SK Bioscience said the latest vaccines can be delivered through the existing distribution network.
The mass-scale global clinical trials by Novavax showed a 90 percent prevention effect for Nuvaxovid against COVID-19, according to SK Bioscience. The company added that Nuvaxoid has shown immunity against the highly contagious omicron variant from Novavax’s recent studies.
